Literature DB >> 11926006

Assessment of the neurotoxicity of oral dihydroartemisinin in mice.

Apichart Nontprasert1, Sasithon Pukrittayakamee, Sompol Prakongpan, Wichai Supanaranond, Sornchai Looareesuwan, Nicholas J White.   

Abstract

High doses of the oil-soluble antimalarial artemisinin derivatives artemether and arteether, given by intramuscular injection to experimental mammals, produce an unusual pattern of selective damage to brainstem centres predominantly involved in auditory processing and vestibular reflexes. We have shown recently, in adult Swiss albino mice, that constant exposure either from depot intramuscular injection of oil-based artemisinin derivatives, or constant oral intake carries relatively greater neurotoxic potential than other methods of drug administration. Using the same model, oral dihydroartemisinin suspended in water was administered once or twice daily at different doses ranging from 50 to 300 mg/kg/day for 28 days. The neurotoxic potential of the oral dihydroartemisinin was assessed and compared to that of oral artemether and artesunate. Oral artemether, artesunate, and dihydroartemisinin had similar neurotoxic effects with no significant clinical or neuropathological evidence of toxicity at doses below 200 mg/kg/day. These data indicate that once and twice daily oral administration of artemether, artesunate and dihydroartemisinin is relatively safe when compared to intramuscular administration of the oil-based compounds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11926006     DOI: 10.1016/s0035-9203(02)90256-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

Review 1.  Schistosomiasis--a century searching for chemotherapeutic drugs.

Authors:  Gabriela Ribeiro-dos-Santos; Sergio Verjovski-Almeida; Luciana C C Leite
Journal:  Parasitol Res       Date:  2006-04-25       Impact factor: 2.289

Review 2.  Artesunate versus quinine for treating severe malaria.

Authors:  David Sinclair; Sarah Donegan; Rachel Isba; David G Lalloo
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

3.  A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.

Authors:  Harpreet Singh; Anang A Shelat; Amandeep Singh; Nidal Boulos; Richard T Williams; R Kiplin Guy
Journal:  J Biomol Screen       Date:  2013-08-29

Review 4.  Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed?

Authors:  Virginia Ramos-Martín; Carmen González-Martínez; Ian Mackenzie; Joachim Schmutzhard; Cheryl Pace; David G Lalloo; Dianne J Terlouw
Journal:  Am J Trop Med Hyg       Date:  2014-05-27       Impact factor: 2.345

5.  Application of the Triazolization Reaction to Afford Dihydroartemisinin Derivatives with Anti-HIV Activity.

Authors:  Sampad Jana; Shabina Iram; Joice Thomas; Muhammad Qasim Hayat; Christophe Pannecouque; Wim Dehaen
Journal:  Molecules       Date:  2017-02-17       Impact factor: 4.411

Review 6.  Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies.

Authors:  Melba Gomes; Isabela Ribeiro; Marian Warsame; Harin Karunajeewa; Max Petzold
Journal:  BMC Infect Dis       Date:  2008-03-28       Impact factor: 3.090

7.  Novel dihydroartemisinin dimer containing nitrogen atoms inhibits growth of endometrial cancer cells and may correlate with increasing intracellular peroxynitrite.

Authors:  Yan Zhu; Christian Klausen; Jieyun Zhou; Xiangjie Guo; Yu Zhang; Hua Zhu; Zhao Li; Jung-Chien Cheng; Shuwu Xie; Wenjie Yang; Ying Li; Peter C K Leung
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

8.  The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage P. falciparum Parasites, DMPK Properties, and the Case for Artemiside.

Authors:  Liezl Gibhard; Dina Coertzen; Janette Reader; Mariëtte E van der Watt; Lyn-Marie Birkholtz; Ho Ning Wong; Kevin T Batty; Richard K Haynes; Lubbe Wiesner
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.